Thymogen (Glu-Trp) and Immune Cell Regulation

Thymogen peptide (Glu-Trp): mechanism and research

Thymogen (sometimes written Thymagen) is one of the smallest peptide bioregulators studied: two amino acids, L-glutamic acid and L-tryptophan (L-Glu-L-Trp). This research-use review covers how it is thought to act on T-lymphocyte differentiation, the cAMP/cGMP balance, stress resistance and abnormal cell growth in animal models, why its D-form (Thymodepressin) does the opposite, and what the literature measured. PrymaLab supplies the 20mg vial, the 10mg nasal spray and the 10mg preloaded pen for research.

Michael Phelps

Founder & Peptide Research Specialist, PrymaLab

Research reference · Last updated July 21, 2026 · ~10 min read

What is Thymogen and where does it come from?

Thymogen, listed in some catalogues as the Thymagen peptide, is a synthetic dipeptide made of L-glutamic acid linked to L-tryptophan (Glu-Trp), written in the chemical literature as glutamyl-tryptophan, with a molecular weight of roughly 333 Da — among the simplest possible peptide structures. It was identified by a team led by Khavinson and colleagues as the active dipeptide fragment of thymalin, a more complex thymus-derived peptide preparation distinct from Thymosin alpha 1, and it belongs to the family of Khavinson short-peptide bioregulators.

Small peptides of this kind are hypothesized to enter cells readily and reach intracellular compartments — including the nucleus — that larger molecules cannot, suggesting a unique mechanism of action. Within the Khavinson model, a dipeptide such as Thymogen is viewed as a signaling molecule that may help guide the molecular activity, tissue repair, and gene expression of immune cells, effectively substituting a defined two-residue sequence for the activity of a much larger thymic protein mixture.

That framing is what earns it the label immunomodulatory peptide rather than a simple stimulant with immune-boosting properties. The natural thymic peptides it was derived from do not push in a single direction, and in these models neither does Thymogen.

It is worth setting the Thymagen peptide against its shelf neighbors, because thymic and repair peptides get catalogued together and are not interchangeable. Thymosin alpha 1 is a 28-residue fragment of prothymosin alpha, approved in several countries as an immune adjuvant and studied in hepatitis B and in vaccine response, acting largely through Toll-like receptor signaling on dendritic cells. Thymosin beta 4 shares the thymic name and almost nothing else: thymosin beta 4 is a 43-residue actin-sequestering peptide whose literature is about tissue repair and regeneration, angiogenesis, and cardiomyocytes after ischemic injury rather than lymphocyte maturation. Vendor listings still file thymosin beta 4 beside Thymogen on the strength of a shared prefix. BPC-157, shelved nearby for the same loose reason, is a gastric pentadecapeptide studied for cellular repair in connective tissue. Thymogen is the only one of the four that is a dipeptide, and the only one whose primary readout is T-cell differentiation. Filing them together as a single category of peptide therapy obscures more than it explains.

How does Thymogen influence cAMP/cGMP signaling?

One proposed route by which Thymogen acts on immune cells is the cyclic nucleotide system — the intracellular messengers cyclic AMP (cAMP) and cyclic GMP (cGMP), which help set the balance between activating and restraining responses. In lymphocyte experiments, Demidov et al. (1991) examined how Thymogen affects cAMP and cGMP levels and the phosphodiesterase enzymes that break cyclic nucleotides down.

The authors reported that the actions of Thymogen appeared to be "connected with the cyclic nucleotide system," and that under sensitization conditions the cAMP/cGMP ratio tended to shift, with the peptide supporting the enzymes responsible for cyclic-nucleotide catabolism. In broader characterizations, Thymogen has also been associated with increased cAMP in T-lymphocytes. Because the cAMP/cGMP ratio helps determine the direction and magnitude of immune responses, adjusting that balance is one plausible way a small peptide could modulate immune-cell signaling. Cyclic nucleotides are among the oldest characterized intracellular signaling molecules, and framing immune modulation as a shift in their ratio rather than as blanket stimulation is close to what the Khavinson group means by immune balance.

How does Thymogen affect T-lymphocyte differentiation?

A recurring theme is that Thymogen may support the maturation, or differentiation, of T-lymphocytes — the cells that coordinate many immune responses and that normally mature under thymic support. Because Thymogen is structurally derived from thymic peptide material produced by the thymus gland, researchers hypothesize it acts as a regulatory signal favoring the development of these cells and potentially influencing natural killer cells within the innate immune system.

In a study by Zhuk and Galenok (1996) examining lymphocyte populations under immune insufficiency or autoimmune disorders, Thymogen exposure was associated with reduced laboratory signs of secondary immunodeficiency and an "activation of T-lymphocyte differentiation." Broader characterizations of L-Glu-L-Trp describe stimulation of T-lymphocyte precursors into mature immunocompetent cells, normalization of the T-helper/T-suppressor (CD4/CD8) ratio, and effects on cytokine output, including the potential to reduce inflammation through the regulation of pro-inflammatory cytokines such as interleukin-2 (IL-2) and interferon (IFN).

The reported profile is broad enough to be worth bounding. T-cell activity and cellular immunity are what these studies actually measure; effects on macrophages and other innate immune cell activities are inferred from cytokine shifts rather than observed directly. The older Russian literature applies the Thymagen peptide across immune deficiencies, autoimmune conditions, chronic inflammation, and a long list of immune-related conditions that includes chronic fatigue syndrome and other forms of chronic illness, but those are clinical case series from the 1990s rather than controlled trials. A peptide that normalizes a CD4/CD8 ratio in one model, such as those studying Lyme or other complex infections, could in principle aggravate autoimmune reactions in another, and nothing in the published record settles that.

Khavinson peptides in a human macrophage cell line

A 2022 study in the International Journal of Molecular Sciences, with Khavinson among the authors, compared five of his peptides on the human monocytic THP-1 line, which can be differentiated into macrophages in vitro: Epitalon, Vilon, Thymogen, the Thymalin peptide complex and Chonluten (Avolio et al. 2022). All five raised tyrosine phosphorylation of mitogen-activated cytoplasmic kinases (Avolio et al. 2022). In differentiated cells challenged with bacterial lipopolysaccharide, all of them inhibited the expression of TNF and the pro-inflammatory cytokine IL-6, and Chonluten also lowered TNF production by monocytes (Avolio et al. 2022). Cells treated with the peptides adhered less to a layer of activated human endothelial cells (Avolio et al. 2022). The authors read the results as the peptides inducing TNF tolerance in monocytes and acting on macrophages as anti-inflammatory molecules (Avolio et al. 2022). Because Thymogen was one of five peptides with broadly similar effects, the study says little about what is specific to Glu-Trp, and it used a single leukaemia-derived cell line in culture.

Does Thymogen affect cellular stress resistance?

Several models suggest Thymogen exposure is associated with greater cellular resilience under stress, potentially through antioxidant pathways. Filippova et al. (1997) studied the peptide during reduced-oxygen states of cardiac muscle cells and reperfusion, reporting an apparent protective effect that — notably — did not appear to depend on common antioxidant or protective mechanisms such as opiate receptors or blockade of calcium entry, though the precise mechanism was not resolved.

Microbial-challenge models point the same direction. Iushchuk et al. (1995) reported that Thymogen supported nonspecific resistance in a Yersinia enterocolitica model, and Khmel'nitskii et al. (1990) observed a less severe spread of Candida in experimental cultures under immunodepression, suggesting Thymogen stimulated the innate immune system and immunocompetent cells toward better activation and defense. Together these hint that the Thymagen peptide may support the functional capacity of immune cells across different challenges. Immune resilience is the frame these papers reach for. What they measure is survival under ischemia, oxidative stress markers, and rates of apoptosis in challenged cultures, which is a much narrower claim than the anti-aging effects the compound gets marketed on.

What about abnormal cell growth?

Because a peptide that supports T cell function, immune-cell activity, and gene expression might, in turn, influence abnormal proliferation, several groups examined Thymogen in tumor models.

These observations are interpreted as consistent with the broader hypothesis that a peptide supporting T cell function and general immune-cell activity may be associated with reduced abnormal cell growth in certain models — not as evidence of anticancer efficacy. No study in this set shows Thymogen acting on cancer cells directly. The proposed route runs through immune surveillance, and the effect sizes are small.

IM862: Glu-Trp in cancer trials outside Russia

The same dipeptide had a second career in Western oncology under the code IM862. The report of a phase II trial in metastatic renal cell carcinoma describes IM862 as the naturally occurring dipeptide L-Glu-L-Trp with immunomodulatory and antiangiogenic properties (Deplanque et al. 2004). The phase III report gives the first residue as L-glutamine instead (Noy et al. 2005), an inconsistency between the two abstracts that is worth knowing when searching the literature.

In AIDS-related Kaposi's sarcoma, a tumour of endothelial origin, a randomised phase II study of a nasal solution in 44 patients reported major responses in 36% and only mild, transient adverse effects such as headache and fatigue (Tulpule et al. 2000). The randomised, double-blind, placebo-controlled phase III trial that followed enrolled 202 HIV-positive patients and found no significant difference in response rate (23% against 21% on placebo), with a shorter median time to progression on IM862 (Noy et al. 2005). Its authors concluded that concurrent antiretroviral therapy had probably contributed to the earlier response estimates (Noy et al. 2005). In 25 patients with metastatic renal cell carcinoma, IM862 produced no objective responses and no grade 2 or 3 toxicity, although plasma VEGF fell (Deplanque et al. 2004). These are the only placebo-controlled human data on Glu-Trp in the reference list, and they come from outside the Khavinson programme.

Why does chirality matter: Thymogen vs Thymodepressin?

One of the most instructive facts about the Glu-Trp scaffold is what happens when you flip its stereochemistry. Thymogen is the L-form (L-Glu-L-Trp) and is immunostimulatory. Its mirror image, the D-form (D-Glu-D-Trp) — marketed as Thymodepressin — exhibits the opposite biological activity: immunosuppression.

For a research audience, this is a clean, memorable illustration of how chirality can reverse a peptide's biological direction: the same two amino acids, the same connectivity, but opposite effects on immune-cell behavior depending on handedness. It also underscores why identity verification (including stereochemistry) matters for a compound this small.

How is research-grade Thymogen characterized?

Because Glu-Trp is a two-residue peptide whose activity is stereochemistry-dependent, identity verification is central. A dipeptide and a 43-residue protein like thymosin beta 4 should never be confusable on a mass-spec trace, yet they are routinely confused on a product page. Research-grade Thymogen (sold as the Thymagen peptide by some suppliers) is typically confirmed by reversed-phase HPLC for purity and mass spectrometry for identity, often utilized in intranasal research models, and supplied for laboratory use only. At PrymaLab, research peptides are tested in PrymaLab's own laboratory (RP-HPLC purity, LC-MS identity), and certificates can be checked at https://prymalab.net/testing/verify/. No specific lot data are asserted in this general reference.

What the published record contains

Published Thymogen figures come from two kinds of source: the Russian product labeling for Timogen, a registered immunomodulator in Russia, and the long-term animal work by Anisimov, Khavinson and Morozov. In that rat study (Biogerontology 2000), female rats received Glu-Trp for 12 months and were followed to natural death; the authors reported a slower Gompertz aging rate and lower tumor incidence than in saline controls. Amounts and schedules from the label and the animal study are not reproduced here.

Frequently asked questions

What is Thymogen?

Thymogen (sometimes referred to as Thymagen) is a synthetic L-Glu-L-Trp dipeptide (~333 Da), the active fragment of the thymic preparation thymalin and a Khavinson short-peptide bioregulator. Despite the shared thymic naming it is unrelated to thymosin alpha 1 and to thymosin beta 4, which are far larger peptides with separate literatures. It is for research use only.

How does Thymogen affect immune cells?

Thymogen (Thymagen) is linked to T-lymphocyte differentiation, a shifted cAMP/cGMP balance (via phosphodiesterase activity), IL-2/IFN/TNF-α signaling, and normalization of the CD4/CD8 ratio in research models.

How does Thymogen support T-lymphocyte differentiation?

Derived from thymic peptide material, it is hypothesized to help immature T-cell precursors mature. Zhuk and Galenok reported activation of T-lymphocyte differentiation and reduced signs of secondary immunodeficiency, though research in other viral models like hepatitis B or autoimmune disorders remains distinct.

What is the difference between Thymogen and Thymodepressin?

They are enantiomers. Thymogen (L-Glu-L-Trp) is immunostimulatory; the D-form (D-Glu-D-Trp, Thymodepressin) is immunosuppressive — opposite activities from the same sequence.

Does Thymogen affect abnormal cell growth?

In animal models, modestly: Bespalov et al. reported ~12% lower tumor occurrence and ~1.7-fold fewer tumors per model, and Anisimov et al. reported reduced radiation-induced carcinogenesis — interpreted as immune-supportive, not anticancer efficacy.

Is Thymogen approved for human use?

Material sold as a research chemical is for laboratory use only and is not intended for human or veterinary use. This article covers cellular mechanisms only.

Related reading

• LL-37 peptide: cathelicidin and immune signalling

References